greenmarketreport4h
MIRA says ketamine-based drug beats current pain treatments in study
The firm says it could offer an alternative to existing treatments while sidestepping addiction concerns that have plagued ...
bovnews4h
Why Did Mira Pharmaceuticals Inc (MIRA) Plummet? Key Factors Explained
In terms of valuation, Mira Pharmaceuticals Inc’s market capitalization stands at $15.52 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...
MIRA says Ketamir-2 outperforms FDA-approved neuropathic pain treatments
MIRA Pharmaceuticals (MIRA) announced that its novel oral ketamine analog, Ketamir-2, has shown greater pain relief compared to FDA-approved ...
MIRA Continues to Post Outstanding Test Results
MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic ...
Sacramento Bee1d
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
"We are fully committed to bringing this breakthrough drug to patients as quickly as possible while backing everything we do ...